Legend Biotech (NASDAQ:LEGN – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Legend Biotech to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, analyst recommendations, valuation and dividends.
Risk and Volatility
Legend Biotech has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Legend Biotech’s competitors have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Legend Biotech and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Legend Biotech | 1 | 6 | 9 | 0 | 2.50 |
| Legend Biotech Competitors | 9923 | 15313 | 45667 | 1602 | 2.54 |
Legend Biotech currently has a consensus target price of $50.85, indicating a potential upside of 190.55%. As a group, “Biotechnology” companies have a potential upside of 126.35%. Given Legend Biotech’s higher probable upside, research analysts clearly believe Legend Biotech is more favorable than its competitors.
Insider and Institutional Ownership
70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Legend Biotech and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Legend Biotech | -0.02% | -0.03% | -0.02% |
| Legend Biotech Competitors | -12,224.09% | -202.33% | -31.23% |
Earnings & Valuation
This table compares Legend Biotech and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Legend Biotech | $1.36 billion | -$296.80 million | -1,750.00 |
| Legend Biotech Competitors | $750.99 million | $11.63 million | -18.78 |
Legend Biotech has higher revenue, but lower earnings than its competitors. Legend Biotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Legend Biotech beats its competitors on 7 of the 13 factors compared.
About Legend Biotech
Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
